PharmaCyte Biotech, Inc.PMCBEarnings & Financial Report
Nasdaq
PMCB Q2 2026 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-1.4M
Net Profit
$-7.4M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-1.24
PharmaCyte Biotech, Inc. Q2 2026 Financial Summary
PharmaCyte Biotech, Inc. reported revenue of $0 for Q2 2026, with a net profit of $-7.4M (N/A margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-7.4M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q2 2026 |
PharmaCyte Biotech, Inc. Annual Revenue by Year
PharmaCyte Biotech, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $0).
| Year | Annual Revenue |
|---|---|
| 2025 | $0 |
| 2024 | $0 |
| 2023 | $0 |
| 2022 | $0 |
Income Statement
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Balance Sheet
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $71.4M | $59.9M | $70.2M | $55.1M | $43.8M | $55.2M | $45.1M | $56.0M |
| Liabilities | $22.5M | $20.4M | $17.2M | $11.6M | $3.6M | $3.3M | $1.5M | $19.4M |
| Equity | $31.4M | $27.6M | $47.7M | $43.5M | $40.3M | $51.9M | $43.6M | $35.2M |
Cash Flow
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-177104 | $-332958 | $-373297 | $-1.1M | $-509893 | $-1.0M | $-2.0M | $-979523 |